A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Olivia was known for flaunting her Size 22 curves for years in a bid to promote body positivity – but she decided to put her ...

Olivia, known as oliviasworld95, is a body positive influencer who has never been afraid to show off her lumps and bumps. But ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

It’s not known whether Cosentyx (secukinumab) is safe to receive while pregnant or breastfeeding. Certain factors may ...

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of ...

Initiation of Phase 2 LOTUS trial: The global study design includes approximately 180 adults with HS to evaluate the efficacy ...

Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...